Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01575756 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap
A Phase 2 study, sponsored by Octapharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01575756 is a Phase 2 study that has completed, run by Octapharma. The registered enrollment target is 22 participants.
The verdict
NCT01575756, a Phase 2 study, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate pharmacokinetic properties, surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/RiaSTAPTM in patients with congenital fibrinogen deficiency
Interventions
- BIOLOGICAL Octafibrin
- BIOLOGICAL Haemocomplettan® P or RiaSTAPTM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01575756
The ClinicalTrials.gov registry entry for NCT01575756 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Octafibrin is the first listed.
NCT01575756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01575756 about?
NCT01575756 is a clinical study titled "Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap". The purpose of this study is to investigate pharmacokinetic properties, surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/RiaSTAPTM in patients with congenital fibrinogen deficiency
What is the current status of trial NCT01575756?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2013-06. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01575756?
The interventions under investigation include: Octafibrin (BIOLOGICAL), Haemocomplettan® P or RiaSTAPTM (BIOLOGICAL).
Who is sponsoring clinical trial NCT01575756?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.